Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* IGF-1 ≥1.3 x upper limit normal (ULN)~* Nadir serum GH concentration ≥0.4 ng/mL in an oral glucose tolerance test (OGTT)~* Patient must have documentation supporting the diagnosis of acromegaly, including elevated GH and/or insulin-like growth factor-1 (IGF-1) levels.~Exclusion Criteria:~* The patient has received long acting somatostatin analogues within 6 months of study entry~* The patient has undergone radiotherapy at any time prior to study entry~* The time between pituitary surgery (if any) and study entry is less than 6 weeks~* The patient suffers from macroadenoma with visual field defects due to chiasmatic compression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BIM 23A760 1 mg (Type: EXPERIMENTAL): None
- BIM 23A760 2 mg (Type: EXPERIMENTAL): None
- BIM 23A760 4 mg (Type: EXPERIMENTAL): None
- BIM 23A760 6 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).